Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow, is consistently preceded by asymptomatic premalignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging, and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. In this systematic review we summarize the currently identified clinical, imaging, and genomic biomarkers suggested to increase the progression risk or shown to be differentially expressed/present between both cohorts of patients. Despite the wide range of proposed markers, there are still no reliable biomarkers to individually predict which MGUS patient will progress to MM and which will not. Research on biomarkers in the progression from MGUS to MM will give more insight in the unknown pathogenesis of this hematological malignancy. This would improve research by elucidating new pathways and potential therapeutic targets as well as clinical management by closer follow-up and earlier treatment of high-risk MGUS patients.
Introduction
Multiple myeloma (MM), also known as Kahler disease or plasma cell (PC) myeloma, is a clonal PC malignancy originating in the bone marrow (BM). The clonal expansion of PCs leads to a homogeneous monoclonal overproduction of a specific type of antibody, called monoclonal protein (M-protein). 1, 2 In 2012, more than 114,000 patients were newly diagnosed worldwide with MM, making it one of the most common hematological malignancies. 3, 4 The International Myeloma Working Group (IMWG) revised in 2014 the definition and diagnostic criteria of MM (Table 1) 2,5,6 such that asymptomatic patients without the typical CRAB criteria (i.e. hypercalcemia, renal insufficiency, anemia, and bone lesions) but with 1 of the new criteria are also diagnosed as MM and are eligible for treatment. These new criteria are on the basis of percentage clonal PCs on BM biopsy, serum free light chain (sFLC) ratio and amount of focal lesions on advanced imaging. 6 The genetic background and disease course are highly heterogeneous. Disease initiation and progression is due to multistep and -factorial processes. This happens in a branching, nonlinear fashion with somatic mutations, epigenetic alterations, translocations, and chromosomal copy number changes. Another level of heterogeneity is added by the PCs' intimate relation with the BM and its microenvironment for growth, survival, etc.
use, stress, comorbid conditions), tumor stage, biology (eg, cytogenetic abnormalities), and therapeutic responses. 10, 11 All cases of MM are consistently preceded by the asymptomatic premalignant stages monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering (asymptomatic) myeloma (SMM). 12 The prestage MGUS is characterized by slightly elevated clonal PCs on the BM biopsy, presence of a small M-protein, and absent CRAB criteria (Table 1) . It is present in approximately 3.5% of the general population older than the age of 50. 2, 12 The prestage SMM is characterized by higher cutoff values for the M-protein and percentage of clonal PCs on BM biopsy but still absence of the CRAB criteria. 12, 13 However, SMM is still a relatively uncommon clinical entity and there is no population-based registry of these patients for prevalence. 14 Because the asymptotic character of both premalignant stages, detection is rather accidental. 15 MGUS as well as SMM have risks to progress ultimately to MM. For MGUS, the risk of progression is approximately 1% per year. 2, 12 For SMM, the risk of progression is higher. Approximately 10% of SMM patients per year will progress to MM in the first 5 years, 3% per year for the next 5 years, and 1% per year for the subsequent 10 years. 13, 16 Currently, reliable biomarkers predicting which MGUS/SMM patients will progress to MM and which will not, are lacking. Consequently, it is impossible to discriminate and identify individuals with a high versus low risk of progression. Whereas only a select percentage of all MGUS and SMM patients will develop MM, all patients need close follow-up monitoring during their life. Therefore, clinical management of MGUS and SMM is on the basis of the "watch and wait" strategy, being clinical follow-up of all patients without treatment until MM progression. 13 This strategy not only causes distress to the patients and their environment, but also the economy (ie, health care) encounters difficulties as a consequence of this approach.
Because of the identification of biomarker(s), high-risk individuals could benefit from close observation and early therapeutic intervention, whereas low-risk individuals can have a reduced frequency of monitoring and avoidance of unnecessary treatments. 13, 17 Also, from a research standpoint, opportunities will arise by new insights and disease understanding, leading to improved treatments and a possible future cure for MM. 12, 17, 18 This definitely underlines the need and importance of biomarkers predicting which MGUS or SMM patients will progress to MM and which will not. Therefore, a literature search (PubMed) was performed to summarize the currently known biomarkers in disease progression to MM. This systematic review addresses the following research question: "Which biomarkers are already available to predict the progression from MGUS to MM?" Our focus was mainly emphasized on the progression from the prestage MGUS to ultimately MM, because Muchtar et al 19 recently published a review focusing on the management of SMM. Comparative studies that reported on markers in MGUS and MM separately were also included. The relevant information is summarized and divided according the different types of biomarkers: clinical, imaging, and molecular (genetic and epigenetic) markers.
Materials and Methods

Research Aims
In this systematic review we intended to investigate the availability of biomarkers predicting the progression from the asymptomatic disease MGUS to the BM cancer MM.
Search Strategy
A systematic search of English-language literature using PubMed (Table 2) was performed along with a manual search of the cited Hypercalcemia: serum calcium >0, 25 mmol/L (>1 mg/dL) higher than the upper limit of normal or >2, 75 mmol/L (>11 mg/dL).
Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 mmol/L (>2 mg/dL).
Anemia: hemoglobin value of >20 g/L below the lower limit of normal or a hemoglobin value < 100 g/L. Bone lesions: 1 or more osteolytic lesions on skeletal radiography, CT, or PET-CT.
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Progressive Biomarkers from MGUS to Myeloma references of the selected articles. The Medical Subject Headings terms, "Multiple Myeloma," "Monoclonal Gammopathy of Undermined Significance," "Disease Progression," and "Biomarkers, Tumor" were used to obtain the available literature. We included all studies performed on patient material, until June 2017 describing biomarkers predicting the progression from MGUS to MM. We excluded studies for any of the following reasons: no abstract available, use of animal models and/or cell cultures, and focus on therapy or diagnosis. A Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart (Figure 1 ) was created to illustrate the number of articles used for this systematic review.
Clinical Markers
One type of marker that could be helpful for the identification of MGUS patients with higher progression risk to transform to MM are the clinical markers ( Table 3) . Most of the time, these markers are easily, simply, quickly, and with minimal invasiveness, detected, making their use more applicable on a larger scale. Several studies described a wide range of different clinical markers, with the potential to discriminate and/or predict the progression from the nonmalignant prestage to the malignancy itself.
Up until now, patients were risk-stratified on the basis of 2 models: one model proposed by the Mayo Clinic and the other by the Spanish Study group. 12 The other model, developed by the Spanish Study group, incorporates the degree of clonality assessed using immunophenotyping and uses multiparametric flow cytometry to differentiate aberrant from normal PCs. Normal PCs express CD138 and intense CD38, whereas aberrant PCs (aPCs) have decreased CD38 expression, increased CD56 expression, and absence of CD19 and/ or CD45. The proportion of BM aPCs within the BM PC compartment (aPC/BM PC) is used as one of the criteria for differential diagnosis between MGUS and MM. The risk of MM progression at 5 years for MGUS and SMM cases having 95% aPC/ BM PC amounted to 25% and 64%, respectively. When MGUS and SMM patients have <95% aPC/BM PC, the risks decreased to 5% and 8%, respectively. In addition to 95% aPC/BM PC, the DNA index has a prognostic value for MGUS patients (on the basis of multivariate analysis). Prognostic stratification is divided into 3 risk categories, on the basis of the presence of 2, 1, or none of the risk factors. For MGUS patients, the risk of MM progression at 5 years for the 3 subgroups amounts to 46%, 10%, and 2%, respectively.
12 Although these models for risk stratification are helpful, they are still not accurate and reliable for implementation in clinical practice. Because of the heterogeneity of the disease, the risk of progression to MM is very individual-dependent.
12,18
Parameters Associated With IMWG Criteria
As earlier described, IMWG redefined myeloma and the diagnostic criteria. A lot of research has focused on these criteria in the search for biomarkers in the progression from MGUS to MM. Dhodapkar et al 22 Cytoplasmic Ig index (CIg), quantitated as described by Papanikolaou et al, 36 is a measure of PC Ig production detected using 2-color flow cytometry of nuclear DNA and CIg (DNA/CIg method). CIg was defined as a prognostic factor for disease progression. In a study of 110 patients with a median follow-up time of 7.8 years, median CIg values declined in the progression from MGUS to SMM to MM (10.5, 5.6, and 3.3, respectively). To exclude the decreasing percentage of highly secreting normal PCs as a reason for this progressive decline, measurements are repeated for strictly aneuploidy cases. The same progressive CIg decline was seen in the transition from MGUS to SMM to MM (16, 9.1, and 3.5, respectively). This study concluded that there is an actual progressive decline in Ig production capacity in the progression to MM. 34 
Angiogenesis
Other potential clinical markers of disease progression are related to angiogenesis and its mechanisms. One identified marker are the levels of serum soluble CD105 (sCD105) by Tsirakis et al. 26 CD105 is a cell membrane glycoprotein, predominantly expressed in angiogenic endothelial cells. This glycoprotein is a powerful marker to quantify tumor angiogenesis, which is the formation of new vessels from preexisting vasculature. In this study, 50 newly diagnosed MM patients and 20 MGUS patients were enrolled. Levels of sCD105 were significantly higher in advanced disease stages. The sCD105 levels in MM patients were significantly higher compared with MGUS patients and the control group, with mean AE SD values of 11.0 AE 5.3 ng/mL, 9.0 AE 2.7 ng/mL, and 8.0 AE 2.1 ng/mL, respectively. In addition, serum transforming growth factor b1 levels were measured, which were significantly lower in MM patients compared with the MGUS patients and control group, whereas it was higher in MGUS patients compared with control subjects. Additionally, interleukin (IL)-6 serum levels were changing with increasing disease stage. In the group of MM patients, IL-6 levels were significantly higher compared with the levels in MGUS patients and the control group. Predominantly, the significance of sCD105 in the progression from MGUS to MM was highlighted in this study. It suggests that sCD105 levels might represent a marker of disease progression from MGUS to MM, addressing the importance of angiogenesis. Another study investigated serum levels of soluble angiopoietin-2 (sAng-2) in patients with hematological neoplasms: 24 MM and 6 MGUS patients. sAng-2 is a growth factor important in neoplastic angiogenesis. The measured sAng-2 levels were lower but not statistically significant in MGUS patients compared to with control subjects. In adversity, sAng-2 levels were elevated in MM patients. This study gives a first indication that serum sAng-2 levels might play a role in the progression from MGUS to MM. 27 Several studies correlated angiogenesis with disease activity. Kuehl and Bergsagel 37 reported low levels of angiogenesis in MGUS, higher levels in SMM, and markedly higher levels in MM. Rajkumar et al 28 also reported a gradual increase in degree of BM angiogenesis, on the basis of microvessel density (MVD) estimation, along the disease progression from MGUS to MM. These studies investigated angiogenesis on protein levels. However, vascular endothelial growth factor (VEGF) expression patterns were also examined. This will be further elucidated in the Molecular Markers section.
Bone Metabolism
Bone metabolism and their associated markers are one of the possible leads to search for progressive biomarkers. Politou et al 31 evaluated the role of bone (remodeling) markers measured in serum samples of MGUS, MM patients, and control participants. By comparing MGUS and MM patients, soluble receptor activator of nuclear factor kB ligand/osteoprotegerin (OPG) ratio, N-telopeptide of collagen type-I (NTX), tartrate-resistant acid phosphatase isoform-5b, and macrophage inflammatory protein (MIP)-1a were significantly decreased, whereas OPG and bone-alkaline phosphatase were increased in MGUS. When MGUS patients and control subjects were compared, only soluble receptor activator of nuclear factor kB ligand/OPG ratio and NTX levels were significantly increased in the MGUS patients. This implies that bone resorption is an early event, already present in the prestage. Although bone Immune System
The role of the immune system and host response in controlling the malignant transformation was investigated. Although the same immune reactivity was detected in MGUS, nonprogressive myeloma, progressive myeloma, and healthy controls indicating general immune competence, a reversible defect in natural killer T-cell function characterizing the progression from premalignant to malignant MM was shown. The clinical progression in MGUS patients was associated with loss of ligand-dependent interferon-g production by invariant natural killer T cells. However, there was no detectable difference in the antitumor killer T-cell function between progressive and nonprogressive myeloma patients. They hypothesized that natural killer T-effector function plays a role in the control of malignant growth of transformed PCs in gammopathies. 30 
Stromal Cell Cyto-and Chemokines
Stromal cell cytokine and chemokine profiles were measured within the context of disease progression. Kline et al 29 
Imaging Markers
As previously mentioned, bone lesions are a common feature of MM patients, whereas they are absent in the prestages MGUS or SMM. This fundamental difference resulted in the idea of searching for markers in the field of imaging (Table 4) . 22, 38, 39 An earlier detection of these lesions would identify patients with a higher risk to progress from the nonmalignant prestage to the hematological cancer.
One of the variables linked to disease progression are the magnetic resonance imaging (MRI)-defined focal lesion number and size. 18 images available MRI data. Focal lesions >1 were detected using MRI imaging of the spine in 3 of the 64 MGUS patients (5%). Univariate analysis revealed a significant association of the presence of focal lesions (>1) on MRI of the spine with an increased progression risk to clinical MM. The multivariate analysis revealed that the presence of >1 MRI-detected focal lesions was not significantly associated, which was probably because of the small study population. However, this study identified the presence of multiple (>1) MRI-detected focal lesions as an independent risk factor. In a multivariate analysis restricted to patients with available MRI data, the presence of >1 MRI-detected focal lesions did not emerge as an independent variable (data not shown). The presence of multiple (>1) focal lesions was detected using MRI in only 9 patients (6%). However, the presence of multiple (>1) MRI-detected focal lesions was an independent predictor of increased risk of disease progression.
Besides bone and osteolytic lesions, angiogenesis is a possible factor playing a role in the progression from MGUS to MM. Increased angiogenesis leads to changes of BM microcirculation. On the basis of this, the use of dynamic contrast-enhanced (DCE)-MRI, an imaging technique able to visualize the changes in microcirculation, in predicting the disease progression was investigated. This study included 60 MGUS patients, 75 newly diagnosed symptomatic MM patients, and 22 healthy controls with DCE-MRI of the lumbar spine. Besides the characterization of microcirculation patterns, also semiquantitative microcirculation parameters were measured. The median of amplitude A and exchange rate constant kep was significantly higher in MGUS and MM patients compared with controls and was significantly different between MGUS and MM. A continuous increase in the median of both microcirculation parameters was observed from controls to symptomatic MM. 39 Hillengass et al 39 hypothesized that in the process of microcirculation augmentation from MGUS to symptomatic MM, the impaired structure of the walls of neoangiogenic blood vessels can be detected before an actual increase in vascular volume appears. So, these findings propose that angiogenesis in the BM increases with progression from premalignant to symptomatic disease. DCE-MRI might be clinically relevant for identifying MGUS patients with higher risk to progress to MM. 12, 39 Although different imaging techniques (such as MRI) are used in the search for predictive imaging biomarkers, the IMWG-defined criteria for bone lesions are still on the basis of the amount of osteolytic lesions determined on conventional skeletal radiography, computed tomography (CT), or positron emission tomography-CT.
2,6,38
Molecular Markers
Several studies suggested that secondary mutational changes in oncogenic pathways are the driving force behind MM progression (Table 5) . 22, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] One such pathway is the deregulation of MYC.
The shift from MGUS to MM might be driven by MYC, because MYC is activated during this transformation. 54 This finding is supported by a recent study, which reported that MYC signaling was activated in 85% of MM patients, whereas it was undetectable in MGUS patients. Using serial BM samples, Xiao et al 41 showed
that five (62.5%) of eight MGUS patients who progressed to MM showed induced expression of MYC. These findings raised the idea that MYC expression is involved in the progression from MGUS to MM. In another study, Chng et al 42 showed that MYC activation is likely to be an early event in myeloma pathogenesis. They also suggested an association between RAS mutations and MYC activation, whereby the MYC protein is stabilized by RAS mutants, prolonging the oncogenic activity of MYC. 42, 44 A different study revealed the presence of RAS mutations in approximately 30% of MM patients, whereas it was rarely seen in MGUS. These data suggest that activating RAS mutations play a role in disease progression.
37,42
Nagoshi et al 43 The Notch family of transmembrane proteins acts as receptors and transcription factors simultaneously. They provide a balance between self-renewal and differentiation in normal as well as cancerous cells. Tumor cells do express the Notch ligands Jagged1 and Jagged2. Interestingly, Colombo et al 55 showed that Jagged2 is deregulated in the MGUS phase, whereas Jagged1 deregulation is only found during progression to MM. They concluded that cancer cells express Jagged1 and Jagged2 through the activation of 2 different mechanisms in different phases of MM progression. 45, 55 Human leukocyte antigen (HLA) class I and II molecules play a key role in the development of T-cell responses against myeloma, stopping the disease progression in early stages. Spanoudakis et al 46 investigated the effect of CD1d-an HLA class I-like moleculeligation on the survival of myeloma cells and expression of CD1d during disease progression. They showed that CD1d is highly expressed in MGUS and even in early myeloma, whereas its expression was reduced and eventually lost in advanced stages. These findings suggest that CD1d expression is a negative predictor for MM cell survival. Another study of Robillard et al 47 48 examined the expression of VEGF, basic fibroblast growth factor (bFGF ), and their receptors in PCs in patients with MGUS and MM. At the mRNA level, they showed no significant difference between MGUS and MM. However, they suggested that the gradual increase in angiogenesis, assessed according to MVD, with disease progression might be related to the cumulative angiogenic effect of increasing numbers of PCs rather than increased VEGF/bFGF expression by individual PCs. Nevertheless, they maintained their hypothesis that increased angiogenesis is causally involved in the progression from MGUS to MM and addressed the need of serial BM samples from individual 
MAGE-C1 and MAGE-A3/6 patients at different stages of the disease to shed more light on the biology behind this progression. An upcoming topic in the search for molecular changes in MM is targeted gene expression profiling (GEP). The University of Arkansas for Medical Sciences group was the first to define a 70-gene classifier (GEP70) with genes linked to short survival, including 7 gene expression clusters, identifying patients with a high risk for short progression-free survival and overall survival. 18 ,49 A GEP70 risk score of > À0.26 seemed to correlate with an increased risk of disease progression and emerged as a significant prognostic variable. The GEP70 associated risk was more evident in the SMM than in the MGUS cohort. These findings showed that an increased GEP70 score was an independent predictor of the risk of transformation from precursors to MM.
18,22
Zhan et al 50 identified with whole genome microarrays 52 genes involved in cancer pathways, with diverse expression patterns in normal, MGUS, and MM PCs. Unsupervised hierarchical cluster analysis of these genes identified MGUS with features of MM and MM with features of MGUS. Of these genes, 41 presented a progressive increased expression pattern along the transition from normal PCs, MGUS, and MM, whereas 4 showed a reduced pattern. Six genes showed higher and 1 a lower expression level in MGUS compared with normal PCs or MM. They classified patients into 4 groups: MM-like MGUS, noneMM-like MGUS, MGUSlike MM, and noneMGUS-like MM. On the basis of their findings, they proposed that MM-like MGUS patients have an increased risk of progression and that these patients might benefit from closer follow-up and earlier treatments. However, this hypothesis needs to be tested on larger cohorts of patients. Other studies did find significant gene expression differences between MGUS and normal PCs, but not between MGUS and MM. 18, 22, 50 However, Ria et al 51 detected 22 genes that were differentially expressed in the 2 latter groups. Of these, 14 genes were downregulated and 8 were upregulated in MM compared with MGUS. Although these data were interesting, GEP analysis of MGUS has the inherent problem that the percentage of PCs is low, by definition <10%, so there is significant contamination with other kinds of cells. Even monoclonal PCs are also likely to be contaminated with normal PCs, which can severely affect gene expression profiles. 12 The group of Jungbluth et al 52 detected cancer/testis antigens (CTAs) in tumor samples from patients with MM. More specifically, CTA members of the type-I melanoma antigen (MAGE ) family appear to contribute to the malignant phenotype. 56 In a previous study from the same research group, 3 CTAs (MAGE-C1/ CT7, MAGE-A3/6, and LAGE-1) were found to be often expressed in MM. The CTA MAGE-C1/CT7 gene was most frequently expressed in MM and might have a prognostic effect in overall survival. 53 However, they only investigated the role of CTA MAGE-C1/CT7 in 3 patients with MGUS. To fully understand the effect of MAGE-C1/CT7 expression on disease progression, more MGUS patients must be investigated. Using the Database for Annotation, Visualization and Integrated Discovery Functional Annotation analysis, we showed gene clusters and common pathways between the previously mentioned genes. Gene ontology analysis showed 2 important biological processes affected by these genes. Six genes (ie, CD1d, CD28, KRAS, jagged 1, NES, and MYC ) were involved in the regulation of cell proliferation, whereas another cluster of six genes (ie, CD28, DCC, KRAS, MAGEA3, NES, and MYC ) were involved in programmed cell death/apoptotic processes. Both processes are known to be dysregulated in several cancers.
Epigenetics
There is a considerable amount of evidence supporting the idea that epigenetic changes, including DNA methylation, histone acetylation, and microRNAs (miRNAs) are important for MM development and progression (Table 6) . 1, 18, [57] [58] [59] [60] [61] [62] During the progression from MGUS to MM, global DNA methylation and gene-specific DNA hypermethylation are the most important epigenetic changes identified so far. Normal B cells, PCs, and MGUS cells have a methylation pattern that is different from that of malignant cells in patients with newly diagnosed MM. 1, 18 Several studies report on the role of promoter methylation in patients with MGUS and MM. 12, [57] [58] [59] On the basis of small numbers, the promoters of p16, E-cadherin (ECAD), death-associated protein kinase (DAPK ), human mutL homolog 1 and suppressor of cytokine signaling 1 have been shown to be increasingly methylated in MM compared with MGUS. 12 One study showed that the prevalence of p16 methylation was increased as the disease progressed; four (24%) of 17 MGUS samples and 178 (34%) of 522 MM samples. However, p16 methylation might not contribute in the transformation process from MGUS to MM because 24% of MGUS patients already harbor p16 methylation. 57 Seidl et al 58 investigated the percentage of methylation of the genes p16, tissue inhibitor of metalloproteinase 3, p15, ECAD, DAPK, p73, RAS-association domain family 1A, p14, O6-methylguanine DNA methyltransferase, and retinoid acid receptor b2 in large numbers of patients with MGUS and MM. Except for p15 and ECAD, most methylation patterns were present in MGUS as well as MM. For p15, methylation was detected in a greater proportion in MM samples. In contrast, they found that ECAD was unmethylated in all MGUS samples, whereas a significant percentage of ECAD methylation was observed in SMM (20%) and MM (27%). This suggests that ECAD methylation is a potential biomarker for disease progression. They also showed in 2 patients with follow-up samples that ECAD was unmethylated at the time of diagnosis but methylated at the time of disease progression. Walker et al 59 analyzed the methylation status of more than 27,000 cytosine-phosphate-guanine sites in normal PCs, MGUS, and myeloma samples. They revealed that at the transformation from MGUS to MM, 1428 genes were hypomethylated. In contrast, they identified gene-specific hypermethylation involving 77 genes only, suggesting the importance of hypo-as well as hypermethylation.
A common DNA methylation change is seen in patients with the t(4;14) translocation, whose myeloma samples have increased genespecific DNA hypermethylation compared with samples of other cytogenetic subgroups. This t(4;14) subgroup overexpresses multiple myeloma SET domain (MMSET), which encodes a histone methyltransferase transcriptional repressor. MMSET mediates histone H3 lysine 36 methylation and its deregulation leads to global changes in histone modifications that promote cell survival, cell cycle progression, and DNA repair. 1 They did not investigate these methylation levels in MGUS patients with t(4;14).
MicroRNAs are an abundant class of regulatory noncoding singlestranded RNA molecules involved in the regulation of gene expression. They play crucial roles in biological processes, including cell motility, differentiation, proliferation, and apoptosis; they also contribute to tumor formation and progression. 60, 63 Divers studies, using BM PCs, found several deregulated miRNAs in MM and MGUS. However, because taking a BM sample is an invasive procedure, Kubiczkova et al 60 identified a profile of 5 miRNAs (miR), which are deregulated in MM and MGUS sera. Levels of miR-744, miR-130a, let-7d, and let-7e were significantly decreased whereas miR-34a was increased in MM and MGUS. However, they did not find miRNAs predicting the progression from MGUS to MM. 60 Jones et al 61 performed miRNA expression profiling of serum samples as well. They showed that the combination of miR-1246 and miR-1308 could distinguish myeloma from MGUS patients, with a sensitivity of 79.2% and specificity of 66.7%. To improve the sensitivity and specificity, analyses of more miRNAs are required. 61, 63 Another study from Pichiorri et al 62 
Critical Note and Discussion
Despite the targeted PubMed search for tumor biomarkers in disease progression from MGUS to MM, still a lot of the selected references needed to be excluded because the focus was elsewhere (ie, therapy, without MGUS and/or MM, etc). Although the use of "biomarkers" as a search term, descriptive studies, purely defining differences between the groups without mentioning their role as potential biomarkers, were recorded too. In fact, the identified biomarkers could be distinguished into 2 different types: factors associated with higher likelihood of progression (predictors) versus markers with only a differential expression or presence compared between the two disease entities. Therefore, an extra column was added to the tables to clearly delineate the identified findings. Because both of the pre-stages as MM itself are still very complex and heterogeneous diseases, it is important to clearly delineate and describe the different study groups in reports. However, this was not always the case. To draw unambiguous conclusions, clearly defined study populations are needed. Furthermore, the use of the same units (ie, g/L, g/dL) and terms would be very valuable. However, the reasons for these difficulties are because of the constant revising of clinical and laboratory parameters.
For the part of clinical markers, a wide range of different potential markers were listed. There was little overlap between the studies but also barely no contradictions or inconsistencies were identified. So, most studies described very diverse parameters, also accentuating/ emphasising the complexness and heterogeneity of the disease. Where the clinical markers were very broad and diverse, the part of imaging markers was more limited and bordered. For the molecular part, several genes (eg, DCC ) were only mentioned once in the literature search for this systematic review. Although these studies showed promising results, more research is necessary to fully unravel the role of those specific genes in the pathogenesis of MM. Some of the included studies did not mention the exact number of patients/ samples for each clinical stage, making it difficult to draw clear conclusions. Remarkably, whereas a broad range of potential biomarkers (ie, mutations, epigenetics, serum levels) were identified, no biomarkers directly/closely related to the BM microenvironment were found in this literature search, even though this microenvironment is known to play an important role in PC growth and survival. 9 Currently, lifelong annual (routine) follow-up is recommended for patients with the asymptomatic, nonmalignant prestages. However, retrospectively, it was already determined that only a small proportion of the MM diagnoses are attributable to serial follow-up (laboratory testing) of MGUS patients. Most of MM is still diagnosed according to the clinical presence of serious MM-related complications and other symptoms. 64, 65 These findings imply that the current watch-and-wait strategy is too standardized and does not work efficiently. However, it has been shown that MM patients with previous knowledge of MGUS have significantly better overall survival than MM patients without this awareness. Even though the watch-and-wait strategy does not work optimally, these findings stress the importance of clinical follow-up in MGUS patients. 66 Therefore, an adapted approach of personalized follow-up is highly required. The identification of biomarkers with a predictive value and associated with a higher likelihood of progression to MM would be of importance in the prediction of which individual MGUS patients will progress to MM and which will not. Further strategies regarding their follow-up and treatment regimens can be guided, on the basis of the early biomarker data. The MGUS patients with identified high-risk markers could have more regular and close follow-up. Additionally, the potential for earlier therapeutic intervention and its usefulness within MGUS might be explored. Because this malignancy is still incurable, an early selection of individuals having the highest chance to progress would/might be of critical importance to be able to treat those patients as early as possible. This approach already showed significant benefits on time to progression and overall survival in SMM patients. However, larger patient cohorts need to be studied to investigate the effect of early treatment on long-term toxicities and outgrowth of more resistant clones. 67, 68 Additionally, because of the heterogeneity and broad range of the different identified markers (clinical, molecular), this will also determine future treatment strategies. Similar to the identified markers, the clinical onset of MM is highly heterogeneous. Disease initiation and progression is because of a multistep and -factorial transformational processes. In MM, cytogenetics and fluorescence in situ hybridization results have prognostic significance. High-risk abnormalities such as hyperdiploidy, deletions (ie, del (13) , del(17p)) and translocations (ie, t(4;14), t(14;16)) are mostly associated with adverse outcome. In contrast, hypodiploidy and translocation t (11;14) are indicated as rather standard risk features. 69 Although this literature search defined a lot of potential markers, it is currently not possible to classify or define individual patients unequivocally in high-or low-risk groups and thus to predict which MGUS/SMM patients will progress to MM. When validated in a larger cohort of patients, the classification of Zhan et al 50 might be used to evaluate MGUS and MM patients to go toward personalized therapy. Treatment might be postponed in patients with MGUS-like MM, whereas subjects with MM-like MGUS might benefit from early therapeutic intervention. This categorization could be useful for SMM as well, because it might provide a distinction between high-risk SMM patients and SMM patients with MGUS-like signatures. A subset of MGUS-like MM was identified and validated with favorable clinical features and longer survival. These results are supported by the observation of MGUS-like signatures in most patients surviving more than 10 years after initiation of total therapy 1.
70
Conclusion
The clonal PC malignancy MM is a very complex disease. Despite many studies, the knowledge about disease initiation and progression is still limited and incomplete. It is known that MM is preceded in practically all cases by an asymptomatic, nonmalignant prestage, called MGUS. The progression risk from MGUS to MM is approximately 1% per year. Reliable biomarkers to discriminate an individual MGUS patient with high risk to progress to MM, are not available. This would improve clinical management of MGUS patients dramatically. Whereas high-risk patients would benefit from frequent monitoring with close follow-up and earlier treatment, low-risk patients should not undergo unnecessary BM and other examinations. More understanding of the pathogenesis underlying both of the premalignant as malignant disease will give insights in new molecular pathways. Additionally, new therapeutic targets can arise from these findings. Until now, no biomarkers predicting the progression from MGUS to MM are identified.
Conclusively, in this systematic review, we discussed the current clinical, imaging, and molecular markers. A whole range of different possible implying factors were identified, increasing the risk of progression from MGUS to MM. However, no reliable markers are identified for use in clinical practice. Confirmation of findings in independent cohort studies are necessary and future research should focus on larger cohorts and study populations to account for the interand intraclonal character of this highly heterogeneous disease. Additionally, serial samples, which are follow-up samples from the same patient at different time points in the disease progression from MGUS to MM, would be a very valuable source of information, improving molecular understanding as well as finding predictive biomarkers.
